Is PROKIDNEY CORP. (PROK) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.5% / 30% | 51.8% / 30% | 0.4% / 30% | 25989.47% / 5% | ✗ NOT HALAL |
| DJIM | 0.5% / 33% | 51.8% / 33% | 0.4% / 33% | 25989.47% / 5% | ✗ NOT HALAL |
| MSCI | 0.7% / 33% | 81.2% / 33% | 0.6% / 33% | 25989.47% / 5% | ✗ NOT HALAL |
| S&P | 0.5% / 33% | 51.8% / 33% | 0.4% / 33% | 25989.47% / 5% | ✗ NOT HALAL |
| FTSE | 0.7% / 33% | 81.2% / 33% | 0.6% / 50% | 25989.47% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -20306.2% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -43.2% | |
| Return on Assets (ROA) | -26.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$126M |
| Free Cash Flow | -$156M |
| Total Debt | $3M |
| Debt-to-Equity | 1.3 |
| Current Ratio | 9.1 |
| Total Assets | $441M |
Price & Trading
| Last Close | $1.77 |
| 50-Day MA | $2.11 |
| 200-Day MA | $2.37 |
| Avg Volume | 847K |
| Beta | 1.8 |
|
52-Week Range
$0.46
| |
About PROKIDNEY CORP. (PROK)
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is PROKIDNEY CORP. (PROK) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), PROKIDNEY CORP. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is PROKIDNEY CORP.'s debt ratio?
PROKIDNEY CORP.'s debt ratio is 0.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.7%.
What are PROKIDNEY CORP.'s key financial metrics?
PROKIDNEY CORP. has a market capitalization of $482M, and revenue of $76,000. Return on equity stands at -43.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.